Luciferase Reporter Cell Line - SW 1353

The SW 1353 cell line is a well-characterized human chondrosarcoma model, originally derived in 1977 from a primary grade II tumor located in the humerus of a female patient. Cultured as an adherent monolayer, these cells are uniquely valued not only as an oncological model but also as a highly reliable in vitro surrogate for primary human chondrocytes. The Luciferase Reporter Cell Line - SW 1353 enhances this foundational orthopedic model through stable lentiviral transduction, engineering the cells to constitutively express the firefly luciferase enzyme. This targeted genetic integration ensures that the modified cells continuously emit a robust, quantifiable bioluminescent signal upon exposure to the substrate D-luciferin. Crucially, this stable modification transforms the standard line into a highly sensitive cellular tracking tool while strictly preserving its original chondrogenic phenotype, distinct metabolic profile, and baseline cellular morphology.

Leveraging its unique chondrocyte-like properties, this reporter cell line is a critical resource for pre-clinical orthopedic, rheumatological, and oncological research. In vivo, the constitutive bioluminescence allows researchers to establish highly reliable localized xenograft mouse models for chondrosarcoma. By utilizing non-invasive bioluminescence imaging (BLI), scientists can continuously monitor primary skeletal tumor proliferation and dynamically evaluate the efficacy of experimental anti-cancer therapeutics in living animals over time, eliminating the need for repeated endpoint sacrifices. In vitro, the model streamlines high-throughput screening for cell viability and cytotoxicity. Because SW 1353 cells consistently upregulate catabolic enzymes like matrix metalloproteinases (MMPs) when stimulated by inflammatory cytokines such as IL-1β, researchers rely on this quantifiable optical readout to rapidly assess the protective effects of novel anti-inflammatory drugs, chondroprotective compounds, and targeted interventions for osteoarthritis and skeletal malignancies.